ZYVERSA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 377.96 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-31
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-12-31 was -1.52M shares.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-09-30 was 0.00 shares.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-06-30 was 1.45M shares.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 377.96K shares.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 44.75K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 377.96K shares 10-K · filed 2026-03-31 | ||
| 2025-09-30 | 377.96K shares 10-Q · filed 2025-11-19 | |||
| 2023-12-31 | -1.52M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -1.52M shares derived: sum of 2 quarters · filed 2024-03-25 | -68.25K shares derived: sum of 3 quarters · filed 2024-03-25 | 44.75K shares 10-K · filed 2024-03-25 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 1.45M shares derived: sum of 2 quarters · filed 2023-11-14 | 1.57M shares 10-Q · filed 2023-11-14 | |
| 2023-06-30 | 1.45M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | 1.57M shares 10-Q · filed 2023-08-21 | ||
| 2023-03-31 | 113.00K shares 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |